Gelteq (GELS): Customer Relationships Signal Rapid Commercialization, Concentration Risk

GelTeq develops and commercializes a proprietary gel-based oral delivery platform and monetizes through product sales, B2B distribution agreements, and manufacturing/commercial partnerships that place its formulations inside third‑party consumer and nutraceutical products. The company’s revenue stream today is primarily driven by licensing of formulations, fulfilment and sales agreements with brand partners, and early-stage distribution contracts that can scale quickly relative to GelTeq’s current revenue base. For a concise briefing on their relationship map and what it means for investors, see Null Exposure’s company page: https://nullexposure.com/

Why customers matter for Gelteq’s investment thesis

GelTeq is at the commercial inflection where a handful of large third‑party agreements convert R&D into repeatable cash flow. That transition defines both upside and risk: large, multi‑year distribution deals can rapidly scale revenue but also concentrate commercial exposure on a small number of partners. Given Gelteq’s modest trailing revenue and high insider ownership, individual customer contracts have outsized impact on valuation and liquidity.

You can review an aggregated profile at Null Exposure for further diligence: https://nullexposure.com/

What the customer roster actually shows

Below I summarize every customer relationship surfaced in public reporting and news coverage. Each entry is a plain-English take with a concise source reference.

Healthy Extracts, Inc. (HYEX) — U.S. commercial launch and expanded partnership

GelTeq’s technology underpins Healthy Extracts’ North American product launches and the two companies have evolved from warehousing/fulfilment to a broader manufacturing and commercial partnership intended to scale U.S. production and global distribution. According to a Yahoo Finance report (March 9, 2026), the initial collaboration began with warehousing and fulfilment arrangements that laid the foundation for Gelteq’s U.S. entry, while a GlobeNewswire release in February 2026 described the relationship as the first phase of a long‑term plan for large‑scale U.S. manufacturing and global distribution. (Sources: Yahoo Finance, March 9, 2026; GlobeNewswire via Manila Times, Feb 11, 2026)

HYEX / Health Extracts Inc. — Repeat orders and product adoption

Healthy Extracts is purchasing Gelteq‑formulated collagen and Mynus Sugar™ gels and has increased order volumes, a sign of product market fit for specific nutraceutical SKUs. MuggleHead reported that Healthy Extracts increased orders (reporting FY2024 activity), confirming active purchase behavior beyond pilot shipments. (Source: MuggleHead, March 2026)

Shenzhen Mana Health Management Co. Ltd. — Three‑year distribution agreement for China

GelTeq signed a three‑year sales agreement with Shenzhen Mana to distribute GelTeq’s nutritional products in China, including minimum annual order commitments of approximately $1.3 million, which materially outstrips GelTeq’s current TTM revenue. Investing.com and other wire reports in May 2026 cited the $1.3M minimum annual commitment as part of the distribution deal. (Source: Investing.com press coverage, May 3, 2026)

Whitney Johns Nutrition — Use of patented technology in branded supplement

Whitney Johns Nutrition is a branded customer using GelTeq’s patented gel technology in a consumer product called BRAIN ACTIVATE, illustrating GelTeq’s route-to-market through white‑label or branded partners in the supplement category. Coverage of this relationship appeared in MuggleHead’s FY2024 reporting on GelTeq’s client base. (Source: MuggleHead, March 2026)

Professional Pickleball Association (PPA) / PPA Tour Australia — Sports and elite program adoption

GelTeq’s platform is already used by elite sports programs across Australia and Asia, including the Professional Pickleball Association’s PPA Tour Australia, which signals early adoption in performance nutrition channels and athlete endorsements. Reporting in Investing.com associated GelTeq’s technology with use by elite sports programs as of FY2025 coverage. (Source: Investing.com / AU Investing, May 2026)

How these relationships change the operating picture

These customer linkages reveal a company operating under a specific commercial profile:

• Contracting posture: GelTeq transacts through multi‑year sales and distribution agreements, fulfilment arrangements, and product supply to branded partners rather than mass direct‑to‑consumer retail today. The three‑year Shenzhen Mana agreement and the Healthy Extracts manufacturing/commercial partnership exemplify longer‑term B2B contracting.
• Commercial concentration: Company financials show TTM revenue of $413k and a signed distribution agreement with minimum annual orders of ~$1.3M, indicating high concentration risk where one or two contracts can dominate near‑term revenue.
• Criticality to partners: For distributors such as Shenzhen Mana and brand partners like Healthy Extracts, GelTeq’s gel formulation is a differentiator that drives product launches; for GelTeq, those partners provide the sales channels that convert R&D into revenue. That asymmetry creates dependency on partner execution and order flow.
• Maturity of relationships: The relationships are early commercial — FY2024–FY2026 reporting shows pilots, expanded orders, and the shift to manufacturing and multi‑year distribution rather than legacy, broad retail placements.

These are company‑level signals rather than constraints tied to any single relationship.

Financial context and risk profile

GelTeq is a very small public company by conventional metrics (market capitalization roughly $6.4m, TTM revenue $413k, trailing operating loss). Insider ownership is high (about 47.5%) while institutional ownership is minimal (under 1%), which concentrates control but limits large institutional support. Given the sizeable minimums embedded in the Shenzhen Mana deal relative to current revenue, the contract is immediately material to GelTeq’s growth trajectory and working capital needs.

Key investor takeaways:

• Upside: Multi‑year distribution and manufacturing agreements can rapidly increase revenue and prove commercial scalability.
• Downside: Single‑counterparty concentration and dependence on a few B2B partners create execution risk; a failed launch or delayed orders would materially affect near‑term cash flow.
• Governance: High insider ownership aligns management incentives with shareholders but reduces institutional oversight.

Bottom line and recommended next steps for investors

GelTeq is converting IP into commercial contracts at pace, and recent agreements demonstrate clear channels to revenue growth; however, the value of those contracts is large relative to current scale, making partner execution the primary investment risk. Investors should monitor order flow and quarterly revenue conversion from the Shenzhen Mana and Healthy Extracts arrangements, and watch for diversification of brand partners beyond the current roster.

For a consolidated view of GelTeq’s relationships, filings, and coverage, visit Null Exposure’s company page at https://nullexposure.com/ — the hub I used to assemble this relationship map.